18. Spinocerebellar degeneration
59 clinical trials,   78 drugs   (DrugBank: 28 drugs),   44 drug target genes,   59 drug target pathways
Searched query = "Spinocerebellar degeneration", "SCD", "Spinocerebellar ataxia type I", "SCA1", "Spinocerebellar ataxia type II", "SCA2", "Spinocerebellar ataxia type III", "SCA3", "Machado-Joseph disease", "Spinocerebellar ataxia type VI", "SCA6", "Spinocerebellar ataxia type VII", "SCA7", "Spinocerebellar ataxia type X", "SCA10", "Spinocerebellar ataxia type XII", "SCA12", "Dentatorubural pallidoluysian atrophy", "Dentatorubropallidoluysial atrophy", "DRPLA", "Naito-Koyanagi disease", "Friedreich ataxia", "FRDA", "Ataxia with vitamin E deficiency", "AVED", "Early-onset ataxia with ocular motor ataxia and hypoalbuminemia", "EOAH"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04519567 (ClinicalTrials.gov) | July 31, 2020 | 17/8/2020 | Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia | A Phase 1 Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia | Friedreich Ataxia | Biological: CTI-1601;Biological: Placebo | Larimar Therapeutics, Inc. | Veristat, Inc.;Metrum Research Group, LLC | Recruiting | 18 Years | N/A | All | 30 | Phase 1 | United States |
2 | NCT04176991 (ClinicalTrials.gov) | December 11, 2019 | 14/11/2019 | Single Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia | A Phase 1 Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia | Friedreich Ataxia | Biological: CTI-1601;Biological: Placebo | Larimar Therapeutics, Inc. | Veristat, Inc.;Metrum Research Group, LLC | Completed | 18 Years | N/A | All | 28 | Phase 1 | United States |